Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Darunavir Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Advanced synthesis of hexahydrofuro[2,3-b]furan-3-ol via patent CN103864813A. Offers cost reduction in API manufacturing and reliable supply chain for pharmaceutical intermediates.
Patent CN117659033B analysis reveals high-purity darunavir intermediate synthesis via photocatalysis offering substantial supply chain and cost advantages for manufacturers.
Patent CN110372641B reveals a novel enzymatic route for hexahydrofurofuranol derivatives, offering high optical purity and cost-effective manufacturing for API supply chains.
Patent CN118530145A details a safer route for Darunavir intermediates. High purity above 98 percent ensures supply chain stability and significant cost reduction in API intermediate manufacturing processes.
Patent CN111235123A reveals a novel carbonyl reductase enabling high-substrate loading biocatalysis, offering significant cost reduction and purity advantages for pharmaceutical manufacturing.
Novel enzymatic route for Darunavir intermediate (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]furan-3-ol offering high optical purity and industrial scalability.
Patent CN111662889B discloses a novel ketoreductase mutant enabling efficient synthesis of Darunavir intermediates with high substrate loading and reduced costs.